CDKN2A and malignant peripheral nerve sheath tumor: In contrast, CDKN2A loss has been reported in as many as 94% of AN.16,19 Taken together, these findings support a model in which CDKN2A loss occurs during the transition from benign PN to AN, whereas TP53, EGFR, and SUZ12 alterations promote evolution to MPNST (Figure 2).